Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kloth JS"'
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure.
Autor:
Bins S; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., Eechoute K; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., de Man FM; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., Oosten AW; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., de Bruijn P; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., Sleijfer S; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands., Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands. a.mathijssen@erasmusmc.nl.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2017 Mar; Vol. 56 (3), pp. 305-310.
Autor:
Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, P.O. Box 2040, 3000 CA, Rotterdam, The Netherlands, j.kloth@erasmusmc.nl., Binkhorst L, de Wit AS, de Bruijn P, Hamberg P, Lam MH, Burger H, Chaves I, Wiemer EA, van der Horst GT, Mathijssen RH
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2015 Aug; Vol. 54 (8), pp. 851-8.
Autor:
Yu H; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2015 May; Vol. 79 (5), pp. 809-19.
Autor:
Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3075EA Rotterdam, The Netherlands., Pagani A; Department of Medical Oncology, Fondazione S. Maugeri, Via Maugeri 10, 27100 Pavia, Italy., Verboom MC; Department of Clinical Oncology, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands., Malovini A; Laboratory of Informatics and Systems Engineering for Clinical Research, Salvatore Maugeri Research and Care Institute, Pavia, Italy., Napolitano C; Department of Molecular Cardiology, IRCCS Fondazione S. Maugeri, Via Maugeri 10, 27100 Pavia, Italy., Kruit WH; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3075EA Rotterdam, The Netherlands., Sleijfer S; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3075EA Rotterdam, The Netherlands [2] Cancer Genomics Netherlands, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology, Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands., Zambelli A; Department of Medical Oncology, Ospedale Papa Giovanni XXIII, P.zza OMS n 1, 24127 Bergamo, Italy., Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3075EA Rotterdam, The Netherlands.
Publikováno v:
British journal of cancer [Br J Cancer] 2015 Mar 17; Vol. 112 (6), pp. 1011-6. Date of Electronic Publication: 2015 Mar 17.
Autor:
Diekstra MH; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Klümpen HJ; Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands., Lolkema MP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Yu H; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands., Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Gelderblom H; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Schaik RH; Department of Clinical Chemistry, Erasmus MC, Rotterdam, The Netherlands., Gurney H; Australian School of Advanced Medicine, Macquarie University, Sydney, Australia., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands., Huitema AD; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands., Steeghs N; Department of Medical Oncology and Clinical Pharmacology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2014 Jul; Vol. 96 (1), pp. 81-9. Date of Electronic Publication: 2014 Feb 24.
Autor:
Lankheet NA; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands., Gadellaa-van Hooijdonk CG; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Cirkel GA; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Mathijssen RH; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Lolkema MP; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Schellens JH; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands., Voest EE; 1] Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Sleijfer S; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., de Jonge MJ; 1] Department of Medical Oncology, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands [2] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands., Haanen JB; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Huitema AD; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands., Steeghs N; 1] Center for Personalised Cancer Treatment, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands [2] Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek, Plesmanlaan 12, 1066 CX Amsterdam, The Netherlands.
Publikováno v:
British journal of cancer [Br J Cancer] 2014 May 13; Vol. 110 (10), pp. 2441-9. Date of Electronic Publication: 2014 Apr 15.
Autor:
Kloth JS; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Klümpen HJ; Department of Medical Oncology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands., Yu H; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands., Eechoute K; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Samer CF; Department of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland.; Swiss Center of Applied Human Toxicology, Basel, Switzerland., Kam BL; Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands., Huitema AD; Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands., Daali Y; Department of Clinical Pharmacology and Toxicology, Geneva University Hospitals, Geneva, Switzerland., Zwinderman AH; Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center Amsterdam, Amsterdam, The Netherlands., Balakrishnar B; Department of Medical Oncology, University of Sydney, Westmead Hospital, Westmead, NSW, Australia., Bennink RJ; Department of Nuclear Medicine, Academic Medical Center Amsterdam, Amsterdam, The Netherlands., Wong M; Department of Medical Oncology, University of Sydney, Westmead Hospital, Westmead, NSW, Australia., Schellens JH; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Drug Toxicology, Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, The Netherlands., Mathijssen RH; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Gurney H; Department of Medical Oncology, University of Sydney, Westmead Hospital, Westmead, NSW, Australia. howard.gurney@sydney.edu.au.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2014 Mar; Vol. 53 (3), pp. 261-269.